首页|产KPC肺炎克雷伯菌感染治疗的研究进展

产KPC肺炎克雷伯菌感染治疗的研究进展

扫码查看
近年来全国耐碳青霉烯类肺炎克雷伯菌(CRKP)分离率逐年上升,且由于其多重耐药、病死率高的特点,给临床治疗带来了严峻挑战。CRKP耐药最主要机制为产碳青霉烯酶,在CRKP中常见的碳青霉烯酶类型为Ambler A、B、D类,C类少见。碳青霉烯酶中最常见的是肺炎克雷伯菌碳青霉烯酶(KPC),属于A类。产KPC肺炎克雷伯菌(KPC-KP)在全球范围内广泛扩散,临床有效治疗药物非常有限。本文就KPC-KP感染治疗的研究进展进行总结,以期为临床治疗提供借鉴意义。
Advances in the treatment of KPC-producing Klebsiella pneumoniae infec-tion
In recent years,the isolation rate of carbapenem-resistant Klebsiella pneunoniae(CRKP)in China has increased year by year.Due to its multidrug resistance and high mortality in patients,CRKP brings severe challen-ges to the clinical treatment.The major mechanism of drug resistance in CRKP is the production of carbapenemases,with Ambler A,B,and D being the common types while Ambler type C comparativly rare.Klebsiella pneumoniae carbapenemase(KPC)is the most common carbapenemase,which belongs to type A.KPC-producing Klebsiella pneumoniae(KPC-KP)widely spreads in the world,with very limited number of effective clinical drugs.In this re-view,advances in the treatment KPC-KP were summarized to provide reference for clinical treatment.

Klebsiella pneumoniaecarbapenemasetreatmentmeropenem/vaborbactamceftazidime/avibactam

马艳秋、吴振超、杜毅鹏、沈宁

展开 >

北京大学第三医院呼吸与危重症医学科,北京 100191

肺炎克雷伯菌 碳青霉烯酶 治疗 美罗培南/法硼巴坦 头孢他啶/阿维巴坦

北京市临床重点专科感染疾病中心建设项目北京大学第三医院临床队列建设项目

010071BYSYDL2019007

2024

中国感染控制杂志
中南大学

中国感染控制杂志

CSTPCD北大核心
影响因子:2.112
ISSN:1671-9638
年,卷(期):2024.23(2)
  • 43